Completely agree.
We are on the verge of a block buster, and being pragmatic I can not see Monepantel not kicking it out of the park in the P2/3 adaptive trial. Overseeing the trial along with daily operations is a big job and to add CEO duties is asking a lot.
Ann: Resignation of Dr Michael Thurn & appointment of John Clark, page-241
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $95.01M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 26.0¢ | 23.5¢ | $437.8K | 1.764M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 277994 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 96080 | 6 |
View Market Depth
| Last trade - 14.54pm 12/06/2024 (20 minute delay) ? |
|
|||||
|
Last
23.5¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 24.0¢ | 25.8¢ | 23.5¢ | 1085645 | ||
| Last updated 15.15pm 12/06/2024 ? | |||||
| PAA (ASX) Chart |